

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

30 May 2026

### Evaluation of interferon treatment in high-risk covid19 patients in Qom

#### Protocol summary

##### Study aim

Determination of interferon treatment in 19-year-old patients with high risk in Qom province.

##### Design

Clinical trial with control group, with parallel, non-blind, randomized group, phase 2 on 60 patients. Blockchain was used for randomization.

##### Settings and conduct

Patients admitted to Shahid Beheshti and Forghani Hospitals with COVID 19 By receiving oxygen by reserve bag, they have less than 94% oxygen saturation Provided you have an entry criterion, According to the pilot study, in two groups of 30 people, it was selected as control and intervention. And enter the study 24 hours after hospitalization And randomly enter the blockade allocation into one of two treatment groups; in addition to receiving treatment protocol from the Ministry of Health, the intervention group will be treated with interferon after obtaining informed consent, and the second group will be treated only with the protocol of the Ministry of Health.

##### Participants/Inclusion and exclusion criteria

Entry requirements: Adulthood, laboratory confirmation of Covid19 infection, dysfunction of the new organ related to Covid19 Conditions of non-entry: intent to commit suicide, sensitivity, or drug sensitivity reaction, ALT above 5 times normal. Use of drugs that are contraindicated with lopinavir / ritonavir, pregnancy, known HIV infection, all vulnerable groups.

##### Intervention groups

In addition to receiving treatment protocol from the Ministry of Health, the intervention group underwent interferon treatment after obtaining conscious consent. And the second group is only treated by the protocol of the Ministry of Health.

##### Main outcome variables

Primary consequences (death within 30 days of hospitalization) and secondary consequences, for example, Results of RT-PCR in lower respiratory samples

#### General information

##### Reason for update

##### Acronym

ندارد

##### IRCT registration information

IRCT registration number: **IRCT20160118026097N3**

Registration date: **2020-05-31, 1399/03/11**

Registration timing: **registered\_while\_recruiting**

Last update: **2020-05-31, 1399/03/11**

Update count: **0**

##### Registration date

2020-05-31, 1399/03/11

##### Registrant information

##### Name

Jamshid Vafaemanesh

##### Name of organization / entity

Qom University of Medical Sciences

##### Country

Iran (Islamic Republic of)

##### Phone

+98 252931933

##### Email address

j.vafaemanesh@muq.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2020-03-20, 1399/01/01

##### Expected recruitment end date

2020-06-20, 1399/03/31

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

##### Trial completion date

empty

## Scientific title

Evaluation of interferon treatment in high-risk covid19 patients in Qom

## Public title

The effect of interferon on the treatment of covid19 patients

## Purpose

Treatment

## Inclusion/Exclusion criteria

### Inclusion criteria:

Laboratory confirmation of Covid19 infection with reverse transcription polymerase chain reaction (RT-PCR) from any diagnostic sampling source A new organ dysfunction related to Covid19 Being an adult

### Exclusion criteria:

Intention to commit suicide (interfering with interferon (IFN) -b1b). Sensitivity or sensitivity reaction to Lupinavir / Ritonavir or IFN-β1b recombinant, including toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema or angioedema syndrome. ALT above 5 times normal Use of drugs that are contraindicated with lopinavir / ritonavir and should not be substituted or discontinued during the study period, such as CYP3A inhibitors. pregnancy. Eligible female participants are tested at gestational age before enrolling in the study for pregnancy. HIV Vulnerable groups

## Age

From **18 years** old to **70 years** old

## Gender

Both

## Phase

3

## Groups that have been masked

*No information*

## Sample size

Target sample size: **60**

## Randomization (investigator's opinion)

Randomized

## Randomization description

Randomization through block allocation

## Blinding (investigator's opinion)

Not blinded

## Blinding description

## Placebo

Not used

## Assignment

Parallel

## Other design features

no

## Secondary Ids

empty

## Ethics committees

### 1

#### Ethics committee

##### Name of ethics committee

Ethics committee of qom University of Medical

Sciences

#### Street address

qom

#### City

qom

#### Province

Ghous

#### Postal code

3719964797

#### Approval date

2020-04-28, 1399/02/09

#### Ethics committee reference number

IR.MUQ.REC.1399.089

## Health conditions studied

### 1

#### Description of health condition studied

COVID19

#### ICD-10 code

#### ICD-10 code description

## Primary outcomes

### 1

#### Description

death within 30 days of hospitalization

#### Timepoint

every day

#### Method of measurement

View

## Secondary outcomes

### 1

#### Description

Days without organ support (for example, supplemental O2, mechanical ventilation, dialysis and vasopressors)

#### Timepoint

Time interval: 28 days

#### Method of measurement

View

### 2

#### Description

Results of RT-PCR in lower respiratory samples

#### Timepoint

Time interval: At the time of entering the study and one week after treatment and repetition every week until the negative sample of the period

#### Method of measurement

test

### 3

#### Description

Body Failure Assessment Scores (SOFA)

#### Timepoint

Time frame: days 1, 3, 5, 7, 14 and 28)

## Method of measurement

check list

## Intervention groups

### 1

#### Description

Intervention group: In addition to receiving treatment protocol from the Ministry of Health, after obtaining informed consent, it will be treated with interferon.

#### Category

Treatment - Drugs

### 2

#### Description

Control group: They are treated only by the protocol of the Ministry of Health

#### Category

Treatment - Drugs

## Recruitment centers

### 1

#### Recruitment center

##### Name of recruitment center

beheshti & forghani hospital

##### Full name of responsible person

hasan adeli

##### Street address

beheshti blv

##### City

qom

##### Province

Ghous

##### Postal code

3719964797

##### Phone

+98 25 3612 2526

##### Email

adeli@muq.ac.ir

## Sponsors / Funding sources

### 1

#### Sponsor

##### Name of organization / entity

Ghous University of Medical Sciences

##### Full name of responsible person

hasan adeli

##### Street address

beheshti blv

##### City

qom

##### Province

Ghous

##### Postal code

3719964797

#### Phone

+98 25 3612 2526

#### Email

adeli@muq.ac.ir

#### Grant name

#### Grant code / Reference number

#### Is the source of funding the same sponsor organization/entity?

Yes

#### Title of funding source

Ghous University of Medical Sciences

#### Proportion provided by this source

100

#### Public or private sector

Public

#### Domestic or foreign origin

Domestic

#### Category of foreign source of funding

empty

#### Country of origin

#### Type of organization providing the funding

Academic

## Person responsible for general inquiries

#### Contact

##### Name of organization / entity

Ghous University of Medical Sciences

##### Full name of responsible person

jamsheed vafaemanesh

##### Position

Associate professor

##### Latest degree

Subspecialist

##### Other areas of specialty/work

Internal Medicine

##### Street address

beheshti blvd

##### City

qom

##### Province

Ghous

##### Postal code

3719964797

##### Phone

+98 25 3612 2526

##### Email

jvafaemanesh@yahoo.com

## Person responsible for scientific inquiries

#### Contact

##### Name of organization / entity

Ghous University of Medical Sciences

##### Full name of responsible person

jamshid vfaemanesh

##### Position

Associate professor

##### Latest degree

Subspecialist

##### Other areas of specialty/work

Internal Medicine

**Street address**

beheshti blvd

**City**

qom

**Province**

Ghoum

**Postal code**

3719964797

**Phone**

+98 25 3612 2526

**Email**

jvafaemanesh@yahoo.com

**Person responsible for updating data**

**Contact**

**Name of organization / entity**

Ghoum University of Medical Sciences

**Full name of responsible person**

jamshid vafaemanesh

**Position**

Associate professor

**Latest degree**

Subspecialist

**Other areas of specialty/work**

Internal Medicine

**Street address**

beheshti blvd

**City**

qom

**Province**

Ghoum

**Postal code**

3719964797

**Phone**

+98 25 3612 2526

**Email**

jvafaemanesh@yahoo.com

**Sharing plan**

**Deidentified Individual Participant Data Set (IPD)**

Yes - There is a plan to make this available

**Study Protocol**

Yes - There is a plan to make this available

**Statistical Analysis Plan**

Yes - There is a plan to make this available

**Informed Consent Form**

Yes - There is a plan to make this available

**Clinical Study Report**

Yes - There is a plan to make this available

**Analytic Code**

Yes - There is a plan to make this available

**Data Dictionary**

Yes - There is a plan to make this available

**Title and more details about the data/document**

All potential data can be shared after people have not been identified

**When the data will become available and for how long**

Start the access period 6 months after printing the results

**To whom data/document is available**

It will be available for researchers working in academic and scientific institutions

**Under which criteria data/document could be used**

According to the rules of the COPE

**From where data/document is obtainable**

jvafaemanesh@yahoo.com

**What processes are involved for a request to access data/document**

Email the responsible author

**Comments**

no